HRP20200076T1 - Kombinacijsko liječenje raka - Google Patents
Kombinacijsko liječenje raka Download PDFInfo
- Publication number
- HRP20200076T1 HRP20200076T1 HRP20200076TT HRP20200076T HRP20200076T1 HR P20200076 T1 HRP20200076 T1 HR P20200076T1 HR P20200076T T HRP20200076T T HR P20200076TT HR P20200076 T HRP20200076 T HR P20200076T HR P20200076 T1 HRP20200076 T1 HR P20200076T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- vrac modulator
- therapy
- anticancer therapy
- use according
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 13
- 201000011510 cancer Diseases 0.000 title claims 11
- 238000011284 combination treatment Methods 0.000 title 1
- 238000011319 anticancer therapy Methods 0.000 claims 22
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 4
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 4
- 229960004768 irinotecan Drugs 0.000 claims 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229960000303 topotecan Drugs 0.000 claims 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000000270 basal cell Anatomy 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000009825 uterine corpus cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (15)
1. VRAC modulator formule I
ili njegova farmaceutski prihvatljiva sol, i terapija protiv raka za uporabu u liječenju raka, pri čemu terapija protiv raka je inhibitor topoizomeraze I odabran od irinotekana, njegovog aktivnog metabolita SN-38 ili topotekana.
2. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu se VRAC modulator primjenjuje prije i/ili istovremeno s i/ili nakon početka terapije protiv raka.
3. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu VRAC modulator je u obliku tableta ili kapsula za oralnu primjenu.
4. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu VRAC modulator je u obliku tekućine za intravenoznu primjenu ili kontinuiranu infuziju.
5. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu rak je otporan na terapiju protiv raka.
6. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu rak je kruti tumor, poput krutog tumora odabranog od sarkoma, karcinoma i limfoma.
7. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu rak je odabran iz skupine koja se sastoji od raka probavnog sustava, raka debelog crijeva, raka dojke, raka pluća (rak pluća ne-malih stanica i rak pluća malih stanica), glioblastoma, raka glave i vrata, zloćudnih melanoma, raka bazalnih stanica kože, raka skvamoznih stanica kože, raka jetre, raka gušterače, raka prostate, analnog raka, raka cerviksa maternice, raka mokraćnog mjehura, raka korpusa maternice, raka jajnika, raka žučnog mjehura, sarkoma, leukemija (mijeloidne i limfne), limfoma, mijelomatoza.
8. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu rak je metastatski rak.
9. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu rak je rak debelog crijeva, poput metastatskog raka debelog crijeva.
10. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od zahtjeva 1 do 9, pri čemu rak je rak dojke, poput metastatskog raka dojke.
11. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od zahtjeva 1 do 9, pri čemu rak je glioblastom.
12. VRAC modulator i terapija protiv raka za uporabu prema bilo kojem od zahtjeva 1 do 9, pri čemu rak je rak pluća.
13. Farmaceutski pripravak koji sadrži efikasnu količinu VRAC modulatora formule I
ili njegovu farmaceutski prihvatljivu sol, terapiju protiv raka i jedan ili više farmaceutski prihvatljivih adjuvansa, pomoćnih tvari, nosača, pufera i/ili razrjeđivača, pri čemu terapija protiv raka je inhibitor topoizomeraze I odabran od irinotekana, njegovog aktivnog metabolita SN-38 ili topotekana.
14. Farmaceutski pripravak koji sadrži efikasnu količinu VRAC modulatora formule I
ili njegovu farmaceutski prihvatljivu sol, i efikasnu količinu terapije protiv raka za uporabu kao lijek, pri čemu terapija protiv raka je inhibitor topoizomeraze I odabran od irinotekana, njegovog aktivnog metabolita SN-38 ili topotekana.
15. Set dijelova koji sadrži VRAC modulator formule I
ili njegovu farmaceutski prihvatljivu sol, i terapiju protiv raka, pri čemu su VRAC modulator i terapija protiv raka formulirani za istovremenu, sekvencijalnu ili zasebnu primjenu i izborno upute za uporabu, pri čemu terapija protiv raka je inhibitor topoizomeraze I odabran od irinotekana, njegovog aktivnog metabolita SN-38 ili topotekana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670325 | 2016-05-17 | ||
| PCT/EP2017/061823 WO2017198700A1 (en) | 2016-05-17 | 2017-05-17 | Combination treatment of cancer |
| EP17726573.3A EP3458052B1 (en) | 2016-05-17 | 2017-05-17 | Combination treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200076T1 true HRP20200076T1 (hr) | 2020-04-03 |
Family
ID=58800797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200076TT HRP20200076T1 (hr) | 2016-05-17 | 2020-01-17 | Kombinacijsko liječenje raka |
| HRP20210572TT HRP20210572T1 (hr) | 2016-05-17 | 2021-04-09 | Kombinacijsko liječenje raka |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210572TT HRP20210572T1 (hr) | 2016-05-17 | 2021-04-09 | Kombinacijsko liječenje raka |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11103481B2 (hr) |
| EP (3) | EP3854393A1 (hr) |
| JP (1) | JP7033554B2 (hr) |
| CN (1) | CN109475535A (hr) |
| AU (1) | AU2017266724B2 (hr) |
| BR (1) | BR112018073518A2 (hr) |
| CA (1) | CA3023202A1 (hr) |
| CY (2) | CY1122541T1 (hr) |
| DK (2) | DK3458052T3 (hr) |
| ES (2) | ES2870805T3 (hr) |
| HR (2) | HRP20200076T1 (hr) |
| HU (2) | HUE047542T2 (hr) |
| LT (2) | LT3458052T (hr) |
| PL (2) | PL3622953T3 (hr) |
| PT (2) | PT3622953T (hr) |
| RS (2) | RS59844B1 (hr) |
| SI (2) | SI3458052T1 (hr) |
| WO (1) | WO2017198700A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3622953T (pt) * | 2016-05-17 | 2021-04-21 | Scandion Oncology As | Tratamento combinado do cancro |
| WO2019165158A1 (en) * | 2018-02-22 | 2019-08-29 | University Of Florida Research Foundation, Incorporated | Il-6 inhibitors and methods of treatment |
| EP3846802A1 (en) * | 2018-09-06 | 2021-07-14 | Scandion Oncology A/S | Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1 |
| WO2020079051A1 (en) | 2018-10-16 | 2020-04-23 | Scandion Oncology A/S | Compounds for treatment of microbial infection |
| AU2022292074A1 (en) | 2021-06-14 | 2023-12-14 | Scandion Oncology A/S | Combination treatments for cancer patients and methods for identifying same |
| EP4104834A1 (en) | 2021-06-14 | 2022-12-21 | Scandion Oncology A/S | Combination treatments for cancer patients and methods for identifying same |
| CA3221558A1 (en) | 2021-06-14 | 2022-12-22 | Peter Michael Vestlev | Methods of increasing the plasma drug exposure of anticancer agents |
| TW202321205A (zh) | 2021-07-16 | 2023-06-01 | 丹麥商斯坎丁腫瘤公司 | Sco-101的熱力穩定形式 |
| EP4197525A1 (en) | 2021-12-20 | 2023-06-21 | Scandion Oncology A/S | Combination of drugs for the treatment of cancer |
| CN117229258B (zh) * | 2022-06-07 | 2024-07-19 | 杭州壹瑞医药科技有限公司 | N-四唑基芳基脲类衍生物及其制备方法和应用 |
| WO2023242235A1 (en) | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| WO2024013058A1 (en) | 2022-07-11 | 2024-01-18 | Scandion Oncology A/S | Salts of sco-101 and methods involving salts |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| DK0977741T3 (da) | 1997-04-22 | 2003-12-01 | Neurosearch As | Substituerede phenylderivater, deres fremstilling og anvendelse |
| EP1514867A3 (en) | 1998-10-22 | 2005-03-23 | NeuroSearch A/S | Substituted phenyl derivatives, their preparation and use |
| IL166040A0 (en) | 2002-08-01 | 2006-01-15 | Neurosearch As | Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
| WO2004111017A1 (en) | 2003-06-17 | 2004-12-23 | Neurosearch A/S | Diphenylurea derivatives and their use as chloride channel blockers |
| JP2007520525A (ja) | 2004-02-04 | 2007-07-26 | ノイロサーチ アクティーゼルスカブ | 二量体のアザ環式化合物及びその使用 |
| JP2008524158A (ja) | 2004-12-17 | 2008-07-10 | ノイロサーチ アクティーゼルスカブ | カリウムチャネル活性化剤として有用なジフェニル尿素誘導体 |
| JP2009530238A (ja) * | 2006-03-14 | 2009-08-27 | ノイロサーチ アクティーゼルスカブ | ジフェニル尿素誘導体及び塩化物チャネル遮断薬又はＢＫＣａチャネル調節薬としてのその使用 |
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| TWI508954B (zh) * | 2012-04-27 | 2015-11-21 | Nat Defense Medical Ct | 雜環融合蒽醌衍生物、其製備方法與醫藥組合物 |
| EP2919009B1 (en) | 2014-03-10 | 2018-09-19 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | LRRC8 proteins and protein complexes and methods for identification of channel modulators |
| ES2662822T3 (es) | 2015-03-04 | 2018-04-09 | Scandion Oncology A/S | Derivados de 4-amino-3-fenilamino-6-fenilpirazol[3,4-d]pirimidina para uso como inhibidores de la BCRP en tratamientos terapéuticos |
| PT3622953T (pt) * | 2016-05-17 | 2021-04-21 | Scandion Oncology As | Tratamento combinado do cancro |
-
2017
- 2017-05-17 PT PT192051043T patent/PT3622953T/pt unknown
- 2017-05-17 RS RS20200088A patent/RS59844B1/sr unknown
- 2017-05-17 LT LTEP17726573.3T patent/LT3458052T/lt unknown
- 2017-05-17 SI SI201730169T patent/SI3458052T1/sl unknown
- 2017-05-17 CN CN201780043536.3A patent/CN109475535A/zh active Pending
- 2017-05-17 HU HUE17726573A patent/HUE047542T2/hu unknown
- 2017-05-17 EP EP21162597.5A patent/EP3854393A1/en active Pending
- 2017-05-17 PT PT177265733T patent/PT3458052T/pt unknown
- 2017-05-17 AU AU2017266724A patent/AU2017266724B2/en active Active
- 2017-05-17 ES ES19205104T patent/ES2870805T3/es active Active
- 2017-05-17 BR BR112018073518-3A patent/BR112018073518A2/pt active Search and Examination
- 2017-05-17 SI SI201730713T patent/SI3622953T1/sl unknown
- 2017-05-17 WO PCT/EP2017/061823 patent/WO2017198700A1/en unknown
- 2017-05-17 US US16/302,195 patent/US11103481B2/en active Active
- 2017-05-17 RS RS20210510A patent/RS61786B1/sr unknown
- 2017-05-17 PL PL19205104T patent/PL3622953T3/pl unknown
- 2017-05-17 DK DK17726573.3T patent/DK3458052T3/da active
- 2017-05-17 PL PL17726573T patent/PL3458052T3/pl unknown
- 2017-05-17 LT LTEP19205104.3T patent/LT3622953T/lt unknown
- 2017-05-17 EP EP19205104.3A patent/EP3622953B1/en active Active
- 2017-05-17 EP EP17726573.3A patent/EP3458052B1/en active Active
- 2017-05-17 JP JP2018560218A patent/JP7033554B2/ja active Active
- 2017-05-17 HU HUE19205104A patent/HUE053744T2/hu unknown
- 2017-05-17 CA CA3023202A patent/CA3023202A1/en active Pending
- 2017-05-17 ES ES17726573T patent/ES2770374T3/es active Active
- 2017-05-17 DK DK19205104.3T patent/DK3622953T3/da active
-
2020
- 2020-01-17 HR HRP20200076TT patent/HRP20200076T1/hr unknown
- 2020-01-27 CY CY20201100070T patent/CY1122541T1/el unknown
-
2021
- 2021-04-09 HR HRP20210572TT patent/HRP20210572T1/hr unknown
- 2021-04-15 CY CY20211100332T patent/CY1124242T1/el unknown
- 2021-07-29 US US17/388,208 patent/US11903927B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200076T1 (hr) | Kombinacijsko liječenje raka | |
| HRP20200696T1 (hr) | Terapija u kombinaciji s inhibitorom topoizomeraze | |
| HRP20200991T1 (hr) | Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate | |
| EP3042652B1 (en) | Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament | |
| HRP20231157T1 (hr) | Azolopirimidin za liječenje poremećaja povezanih s rakom | |
| HRP20170791T1 (hr) | Smjesa rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil]-fosfata | |
| JOP20190090B1 (ar) | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان | |
| JP2015096544A5 (hr) | ||
| JP2011079858A5 (hr) | ||
| JP2013126979A5 (hr) | ||
| HRP20201819T1 (hr) | Farmaceutski pripravak za liječenje raka koji sadrži laktatnu metalnu sol | |
| JP2016528162A5 (hr) | ||
| RU2010140890A (ru) | Улучшенные способы противоопухолевого лечения | |
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| US10702494B2 (en) | Method for cancer treatment | |
| JP2016522202A5 (hr) | ||
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| CN103372210A (zh) | 小檗碱联合化疗药物在抗肿瘤治疗中的应用 | |
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
| JP2014530181A5 (hr) | ||
| CN103768042A (zh) | 甘草查尔酮a在制备抗癌药物或保健品中的应用 | |
| MX2023005295A (es) | Tratamiento contra el cancer resistente a platino. | |
| RU2015114967A (ru) | Производные ингенола, применяемые для лечения рака | |
| CN104434939B (zh) | 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用 |